Armata Pharmaceuticals Inc (ARMP)
2.59
-0.06
(-2.26%)
USD |
NYAM |
May 17, 16:00
2.64
+0.05
(+1.93%)
After-Hours: 20:00
Armata Pharmaceuticals Cash from Financing (TTM): 59.32M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 59.32M |
December 31, 2023 | 53.99M |
September 30, 2023 | 53.53M |
June 30, 2023 | 28.76M |
March 31, 2023 | 28.98M |
December 31, 2022 | 44.02M |
September 30, 2022 | 51.55M |
June 30, 2022 | 51.61M |
March 31, 2022 | 51.57M |
December 31, 2021 | 25.52M |
September 30, 2021 | 18.91M |
June 30, 2021 | 18.89M |
March 31, 2021 | 19.38M |
December 31, 2020 | 23.21M |
September 30, 2020 | 22.78M |
June 30, 2020 | 22.72M |
March 31, 2020 | 32.39M |
December 31, 2019 | 8.975M |
September 30, 2019 | 21.43M |
June 30, 2019 | 15.02M |
March 31, 2019 | 4.841M |
December 31, 2018 | 12.45M |
September 30, 2018 | -0.206M |
June 30, 2018 | 5.589M |
March 31, 2018 | 15.49M |
Date | Value |
---|---|
December 31, 2017 | 8.671M |
September 30, 2017 | 12.13M |
June 30, 2017 | 12.73M |
March 31, 2017 | 7.021M |
December 31, 2016 | 7.226M |
September 30, 2016 | 3.971M |
June 30, 2016 | 3.987M |
March 31, 2016 | 0.396M |
December 31, 2015 | 12.78M |
September 30, 2015 | 12.78M |
June 30, 2015 | 12.78M |
March 31, 2015 | 12.38M |
December 31, 2014 | 0.00 |
September 30, 2014 | 16.91M |
June 30, 2014 | 16.91M |
March 31, 2014 | 24.91M |
December 31, 2013 | 25.89M |
September 30, 2013 | 8.974M |
June 30, 2013 | 8.974M |
March 31, 2013 | 0.976M |
September 30, 2009 | 0.00 |
June 30, 2009 | -0.258M |
March 31, 2009 | -0.258M |
December 31, 2008 | -0.259M |
September 30, 2008 | -0.427M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
8.975M
Minimum
Dec 2019
59.32M
Maximum
Mar 2024
32.63M
Average
27.14M
Median
Cash from Financing (TTM) Benchmarks
AIM ImmunoTech Inc | 0.485M |
Perspective Therapeutics Inc | 167.19M |
Protalix BioTherapeutics Inc | 10.43M |
Electromed Inc | 0.149M |
Xtant Medical Holdings Inc | 20.30M |